PRIMARY STUDY
Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial
Key Findings: In patients with chronic kidney disease (CKD) and hyperuricemia, treatment with the novel non-purine, selective xanthine oxidase inhibitor called Febuxostat, reduced serum uric acid (UA) levels in the blood, and reduced liver-type fatty acid-binding protein (L-FABP), albumin, and beta 2 microglobulin β2MG in the urine, suggesting it's therapeutic potential and renoprotective properties.
Type of Study: Clinical Trial
Study Sample Size: 40
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2015
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Route of Administration: Endogenous
Citation: Tanaka K, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol. 2015; 19:1044-53. doi: 10.1007/s10157-015-1095-1
Authors: Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Hayashi Y, Asahi K, Terawaki H, Watanabe T
